Navigation Links
Feasibility of Multiplexing Bio-Plex Total Target and Phosphoprotein Assays

Qian Gao, Joella Blas, and Efthalia Gerasimopoulos, Bio-Rad Laboratories, Inc., Hercules, CA 94547 USA


Introduction
Bio-Plex assays allow detection of mutiple target proteins in a small volume of sample. The assays are based on detection of signal from tagged fluorescent beads (xMAP technology) that have bound to each target protein. Typically, each type of bead is conjugated with distinct antibodies that recognize one of the target proteins. Appropriate sets of beads are then selected that enable simultaneous, or multiplex, assays of the proteins of interest in the sample. Bio-Plex phosphoprotein assays report the level of a protein that is phosphorylated at a specific site or sites, while total target assays report the level of the protein regardless of its phosphorylation state.

Typically, because of epitope binding competition for the same target protein, a total target assay should not be multiplexed with the corresponding phosphoprotein assay. Also, because the pair of antibodies used in the two assays differ, the signal from a total target assay may not be comparable to that of its corresponding phosphoprotein assay, so it is not appropriate to calculate the percentage of phosphorylated target protein using the results from a total and a phosphoprotein assay in the same reaction. However, because maximizing the number of assays in a particular reaction is desirable to conserve sample, in this note, we present results from a case study testing the feasibility of multiplexing a Bio-Plex total target assay with Bio-Plex phosphoprotein assays for different target proteins. This study was designed to answer two questions:

Can a total target assay be multiplexed with phosphoprotein assays?
Can a total target assay detect differences in protein concentration among samples?


Methods
We designed the study using HEK 293 cells, which respond to UV treatment by increasing the level of phosphorylation of several proteins. All proteins selected for the phosphoprotein assays in this study are activated by this treatment. The multiplex run (6-plex) included the following targets:

Total ERK2
Phospho-p53 (Ser15)
Phospho-p70 S6 kinase (Thr421/Ser424)
Phospho-ATF-2 (Thr71)
Phospho-JNK (Thr183/Tyr185)
Phospho-c-Jun (Ser63)

Untreated and UV-treated HEK 293 cell lysates were prepared according to methods detailed in the Bio-Plex phosphoprotein assay instruction manual. Both untreated HEK 293 and UVtreated HEK 293 cell lysates were tested at three different protein concentrations to test dose-response characteristics of the assays. Blank wells were included in the run, with cell lysis/assay buffer used to replace the cell lysate. Duplicates were run for each sample.


Results and Discussion
Total Target Assays Can Be Multiplexed With Phosphoprotein Assays for Distinct Targets
Data from a multiplex run of five phosphoprotein assays with a total ERK2 assay are presented in Figure 1. To show the results clearly, each phosphoprotein signal was plotted together with the total ERK2 assay signal. Although the phosphorylation levels found between UV-treated and untreated cell lysates varied, the total ERK2 signal level at the same protein concentration was very consistent between treatments, indicating that none of the phosphoprotein assays interfered with the total target assay in this multiplex run.

For all tested phosphoprotein targets, the level of detected phosphorylation increased in HEK 293 cells in response to UV treatment, with the extent of increase depending on the phosphoprotein, as expected. The most dramatic signal increase was detected for phospho-c-Jun (Ser63) (Figure 1E).

At 0.6 g/ml protein, there was more than a 40-fold increase in phospho-c-Jun signal detected in UV-treated HEK 293 compared to untreated cell lysate. Notably higher levels of phosphorylation were also detected for phosphorylated p70 S6 kinase and phospho-ATF-2 assays in UV-treated cell lysates. The signals for untreated cell lysates were consistently low across all diluted samples. The low signals, around 60 70 MFI, in untreated cell lysates made the ratio of UV-treated to untreated as high as 76 at 12 g of total protein concentration. Lower phosphorylation levels were detected for phospho-p53 (Ser15) and phospho-JNK (Thr183/Tyr185), but the signal differences between untreated and UV-treated cell lysates were still significant at all tested protein concentrations.

Data from this 6-plex run (one total target assay multiplexed with five phosphoprotein assays) suggest that it is practical to mutiplex Bio-Plex total target assays with Bio-Plex phosphoprotein assays, provided that the targets are not the same.

Total ERK2 Assay Results Correlated With Protein Concentration
The total ERK2 assay showed consistent results in both untreated and UV-treated HEK 293 cell lysates. The signal for total ERK2, though not linear, showed a good dose-response over the range from 12 to 0.6 g/ml. The same was true for the phosphoproteins in each of the treated samples. These results emphasize the importance of establishing the dose-response relationship between the concentration of each protein target and the corresponding signal when a specific cell lysate sample is tested. These results demonstrate that multiplexing a total assay with five phosphoprotein assays can detect differences among samples with different protein concentrations.


Conclusions
The results of this study successfully answered the questions posed, demonstrating that:
A total target assay can be multiplexed with phosphoprotein assays, provided the target proteins are different
A total target assay can detect differences in protein concentrations among samples

xMAP is a trademark of Luminex Corporation. The Bio-Plex suspension array system includes fluorescently labeled microspheres and instrumentation licensed to Bio-Rad Laboratories, Inc. by the Luminex Corporation.

Information in this tech note was current as of the date of writing (2005) and not necessarily the date this version (Rev A, 2005) was published.


back to top
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A
2. Detection of Phosphorylated and Total ERK and p38 MAPK by Bio-Plex Assay, ELISA, and Western Blotting, Rev A
3. Correlation of Bio-Plex Suspension Array Reader Validation With Multiplex Cytokine Assay Performance, Rev A
4. Selection of Standards for Bio-Plex Cytokine Assays, Rev A
5. Application of the Bio-Plex Cell Lysis Kit in Western Blot Analysis of Phosphoproteins, Rev A
6. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
7. New Kit Generates Exceptionally Pure Total RNA for RT-PCR
8. High-Throughput Isolation of Total RNA
9. Isolate and Analyze Total RNA from Cells Harvested by Laser Capture Microdissection
10. Fast Isolation of Total RNA from Small Numbers of Cells
11. Total RNA Isolation Protocol 1,2,3
Post Your Comments:
(Date:10/7/2008)...ected to aid drug discovery by allowing for the ra...gle reaction, ST. LOUIS, Oct. 7 /PRNewswire-First...o announce that it has signed an exclusive licensi...bana-Champaign allowing,Sigma-Aldrich to offer res...ogates for use in Suzuki-Miyaura coupling to resea...
(Date:10/7/2008)...s to focus on new patient data supporting the Ross...ynerGraft processed human heart .../- CryoLife, Inc. (NYSE: C...ocessing company, announced today,that cardiovascu...e in the,Ross Summit 2008, a two-day surgical cong...
(Date:10/7/2008)...Institutes of Health, The Infectious Disease Resea...Launch and Board of Advisors, SEATTLE, Oct. 7 /PR...,Initiative today announced its first acquisition ...osis (TB) drug candidates. Agreements were reached...nd the Microbial Chemistry,Research Foundation (MC...
(Date:10/7/2008)... Oct. 7 /- BioEnergy International, L...r and manufacturer of,next-generation, renewable b...f Norman R. Augustine to its Board of Advisors eff...f distinguished leadership and innovation,at the h...g in his role as,Chairman and Chief Executive Offi...
Breaking Biology Technology:Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 2Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 3CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 2CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 3CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 4Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 2Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 3Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 4Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 5BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 2BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 3
... Accelerate Madison hosted a discussion this fall...I wanted to know if information technology (IT) an...ogether, or having a one-night stand. So, I talke...ed, Does IT give his company a competitive advanta...edical device capital equipment sector, is revolut...
...MADISON, Wis.-- Sonic Foundry, Inc. , a rich media...ique Wisconsin Department of Transportation (WisDO...m. , ,In a rare engineering feat, WisDOT will floa...dge in La Crosse, Wis., and connect it to permanen... wide and 87 feet high. , ,Using Mediasite Live, W...
...MILWAUKEE-- Hal Leonard Corporation , (HLC) headq...usic publisher, and MakeMusic! Inc. , the leading...ay that will be bundling SmartMusic with HLCs popu...Elements 2000 for Band Book 1 and Essential Elemen...nology-based music practice system with over 20,00...
... Studies suggest 1500 Megawatts of Electricity Cou...y in the Wisconsin, especially after the Californi...going a paradigm shift. There was a time when the ... resided with the utilities, the federal governmen... while the environmental component of each decisio...
Other Biology Technology:TomoTherapy: A Marriage of IT and Biotech 2Wisconsins Businesses Can Become Environmental Leaders 2Wisconsins Businesses Can Become Environmental Leaders 3
(Date:10/7/2008)... In geology as in cancer research, the silver bul...ways turns out to be wrong. , For geologists who...ant asteroid plunging to earth. , But an asteroi...five mass extinctions, said USC earth scientist Da...ped out the dinosaurs. , "The other four have no...
(Date:10/6/2008)... EAST LANSING, Mich. Michigan State University p...he genetic puzzle that controls how plants respond...rs to create new varieties of crops that flourish ... found that the gene bZIP28 helps regulate heat st...of the mustard family used as a model plant for ge...
(Date:10/6/2008)... New York, NY, October 6, 2008 -- A research stud... bacteria may provide some protection from develop...tant step towards understanding how and why type 1...ntial cures. , The study, reported this week in...hygiene hypothesis," that exposure to an appropria...
(Date:10/6/2008)... New Orleans, LA Dr. Eugene Woltering, the Jame...at LSU Health Sciences Center New Orleans School o...Professor of Physiology, have been awarded a US Pa...ood vessels critical to the growth of cancerous tu...ty, and psoriasis. , Apolipoprotein A-I is the m...
Breaking Biology News(10 mins):Extinction by asteroid a rarity 2MSU scientists find new gene that helps plants beat the heat 2JDRF funded study links 'hygiene hypothesis' to diabetes prevention 2LSUHSC awarded patent for compound inhibiting cancer and other diseases 2Technology Advance Could Help Paralyzed 3578 1Kidney disease treatment may harm patients 3576 1Anesthesia Drugs Market to Grow to 244 3 Billion by 2011 as Populations and Uses for Anesthesia Increase 3574 1Anesthesia Drugs Market to Grow to 244 3 Billion by 2011 as Populations and Uses for Anesthesia Increase 3574 2WallSt net Updates Investment Community Through All New Interview With Ingen Technologies 3572 1WallSt net Updates Investment Community Through All New Interview With Ingen Technologies 3572 2
...o gene therapy involves short DNA fragments (inter...their "translation" into the corresponding, diseas...efficient and targeted delivery of RNA into the ce...iversity have chosen to use carbon nanotubes as th... to successfully introduce RNA fragments that "swi...
... suggests that the majority of cases of drug-resis...reatment for the disease may be due to new infecti...re studies the research, in the March 15 issue of ...jor shift in strategy for controlling TB. , A majo...B is that the organism can become progressively re...
...r process that enables cells to turnover their con...y is initiated in tumor cells by chemotherapy and ... to tumor cell death or helps tumor cells survive ... a mouse model of B cell lymphomas, researchers fr...hat autophagy represents a survival mechanism for ...
...esearchers studying mosquitoes have produced the f...omes that activate ?and are apparently evolving ?i...p will allow researchers to narrow their focus to ...development of animals. Such information will help...mates and identify which disease-carrying vectors ...
Other Biology News:Batten down the hatches against HIV 2New research may overturn conventional wisdom on drug-resistant tuberculosis 2New research may overturn conventional wisdom on drug-resistant tuberculosis 3Mosquito genes explain response to climate change 2Mosquito genes explain response to climate change 3
Novagen's Calf Liver tRNA is qualified for use in reticulocyte lysates for in vitro translation, and is the same supplement used in the Red Nova Lysate .
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182
BACE (CT) rabbit polyclonal antibody
Biology Products: